Myricetin Inhibits SARS-CoV-2 Viral Replication by Targeting Mpro and Ameliorates Pulmonary Inflammation
The coronavirus disease 2019 (COVID-19) has spread widely around the world and has seriously affected the human health of tens of millions of people. In view of lacking anti-virus drugs target to SARS-CoV-2, there is an urgent need to develop effective new drugs. In this study, we reported our disco...
Main Authors: | Ting Xiao, Mengqi Cui, Caijuan Zheng, Ming Wang, Ronghao Sun, Dandi Gao, Jiali Bao, Shanfa Ren, Bo Yang, Jianping Lin, Xiaoping Li, Dongmei Li, Cheng Yang, Honggang Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-06-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.669642/full |
Similar Items
-
Genetic Surveillance of SARS-CoV-2 Mpro Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
by: Jonathan T. Lee, et al.
Published: (2022-08-01) -
Docking and Electronic Structure of Rutin, Myricetin, and Baicalein Targeting 3CLpro
by: Sergio A. de S. Farias, et al.
Published: (2023-10-01) -
Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L
by: Elisa Costanzi, et al.
Published: (2021-10-01) -
Investigation of Thiocarbamates as Potential Inhibitors of the SARS-CoV-2 Mpro
by: Katarzyna Papaj, et al.
Published: (2021-11-01) -
Myricetin Nanofibers Enhanced Water Solubility and Skin Penetration for Increasing Antioxidant and Photoprotective Activities
by: Tzu-Ching Lin, et al.
Published: (2023-03-01)